Cautious Hold Rating on Adicet Bio Amid Early-Stage Clinical Developments and Uncertain Outcomes

H.C. Wainwright analyst Edward White has reiterated their neutral stance on ACET stock, giving a Hold rating today.

Edward White has given his Hold rating due to a combination of factors surrounding Adicet Bio’s current clinical developments and future prospects. The company is actively working on its ADI-001 product, which is in the early stages of clinical trials for various autoimmune diseases, including lupus nephritis. While the initial data for ADI-001 is expected in the first half of 2025, the outcomes and potential market impact remain uncertain at this stage.
Additionally, Adicet Bio is progressing with its ADI-270 candidate, targeting CD70+ cancers, with preliminary data also anticipated in the first half of 2025. Despite the promising potential of these therapies, the clinical trials are still in early phases, and the results are yet to be determined. This uncertainty, coupled with the inherent risks in drug development, likely influenced White’s decision to maintain a Hold rating, suggesting a cautious approach until more definitive data is available.